China’s SFDA To Air Test Results Of Lethal Human Immunoglobin
This article was originally published in PharmAsia News
Executive Summary
Chinese authorities have completed a week-long test of human immunoglobin believed connected with six deaths in the Jiangxi Province. The State FDA recalled all 6,247 bottles of the suspected antibody produced by Jiangxi Boya Pharmaceutical. The test results have not been determined, but an SFDA spokeswoman said they would be released as soon as they are concluded. (Click here for more
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.